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Abstract: Statins are receiving increasing attention in the ophthalmic field. Their activity as 3-hydroxy-
3-methylglutaryl–CoA (HMG–CoA) reductase inhibitors is clinically used to regulate cholesterol
levels and leads to pleiotropic effects, which may help in the management of diabetes-related ocular
pathologies. This work aims to design bioinspired contact lenses (CLs) with an affinity for atorvastatin
by mimicking the active site of HMG–CoA reductase. Sets of imprinted and nonimprinted 2-
hydroxyethyl methacrylate (HEMA) hydrogels were synthesized, varying the contents in functional
monomers that bear chemical groups that resemble those present in HMG–CoA reductase, namely,
ethylene glycol phenyl ether methacrylate (EGPEM), 2-aminoethyl methacrylate hydrochloride
(AEMA), and N-(3-aminopropyl) methacrylamide hydrochloride (APMA). The hydrogels were
characterized in terms of suitability as CLs (solvent uptake, light transmission, mechanical properties,
and biocompatibility) and capability to load and release atorvastatin. Three sterilization protocols
(steam heat, gamma radiation, and high hydrostatic pressure) were implemented and their effects on
hydrogel properties were evaluated. Copolymerization of AEMA and, particularly, APMA endowed
the hydrogels with a high affinity for atorvastatin (up to 11 mg/g; KN/W > 200). Only high hydrostatic
pressure sterilization preserved atorvastatin stability and hydrogel performance. Permeability studies
through the porcine cornea and sclera tissues revealed that the amount of atorvastatin accumulated
in the cornea and sclera could be effective to treat ocular surface diseases.
Keywords: atorvastatin; bioinspired contact lenses; molecularly imprinted hydrogels; computational
modeling; sterilization; controlled drug release
1. Introduction
Statins, 3-hydroxy-3-methyl-glutaryl coenzyme A (HMG–CoA) reductase inhibitors,
are a class of lipid-lowering drugs widely prescribed for regulation of cholesterol levels
and notably contributing to the prevention of cardiovascular diseases [1]. They act on a
key step of the metabolic pathway for the biosynthesis of intracellular cholesterol, i.e., the
mevalonate pathway [2]. In addition to lowering cholesterol, statins are recognized to
have pleiotropic effects, which are shown as anti-inflammatory, antiproliferative, neuro-
protective activities, etc. [3]. Although there are not commercially available ophthalmic
formulations of statins, oral administration has been associated with beneficial effects on
eye conditions. With respect to ocular surface inflammation, preliminary data suggest that
oral administration of statins may increase the regenerative quality of corneal repair pro-
moting corneal wound healing [4]. Nevertheless, the effect of statins on dry eye symptoms
and meibomian gland function is still unclear [5]. Statins cholesterol-lowering function
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may have a role in the prevention of cataracts since cholesterol synthesis is required to
regulate the metabolism of the crystalline [6] and accumulation of cholesterol in human
lens fibers facilitates cataractogenesis [7]. In open-angle glaucoma, statins may increase
retinal and choroidal blood flow maintaining the optic nerve and retinal nerve fiber layer
health, reducing the severity of glaucoma [8]. In age-related macular degeneration, statins
may reduce drusen formation between the retinal pigment epithelium and Bruch mem-
brane [9]. In diabetic retinopathy, statins appear to reduce hard exudates formation [10]
and macular edema [11], improve the endothelial structure, function, blood flow velocity,
and vascular resistance, reducing microaneurysm formation and leakage or hemorrhage
from new vessels [12]. Overall, systemic delivery of statins is revealing beneficial to treat
ophthalmic disorders affecting anterior and posterior segments. These therapeutic effects
could be improved if efficient ocular formulations are developed.
Atorvastatin calcium is a synthetic statin with relatively moderate lipophilicity and
low molecular weight, which may be able to penetrate the ocular structures if topically
applied [13,14]. Preclinical studies have demonstrated that atorvastatin (50 µM) oph-
thalmic solutions have a greater immunomodulatory effect on activated human T cells than
lovastatin and simvastatin solutions [15]. Moreover, atorvastatin drops can be safely admin-
istered for long-term treatment of dry eye and blepharitis, showing tear film stabilization
and anti-inflammatory effects [16].
Diabetes mellitus is a metabolic disease defined by elevated blood glucose that leads
to macrovascular (e.g., coronary heart disease, peripheral vascular disease, and stroke)
and microvascular (e.g., retinopathy, nephropathy, and neuropathy) complications [17,18].
Dysregulation of blood glucose can cause alterations in a multitude of anterior and poste-
rior structures of the eye [19]. The most well-studied manifestation is diabetic retinopathy,
although it is estimated that diabetic keratopathy affects up to two-thirds of diabetic
patients [17,20,21]. Diabetic keratopathy complications could be superficial punctate ker-
atitis, corneal erosions, and persistent epithelial defects and, in advanced stages, loss of
the basement membrane and subsequent stromal ulceration [19]. Corneal sensitivity is
also impaired in diabetes and may predispose to bacterial corneal ulcers, compromising
the healing mechanism [22]. Furthermore, tear film secretion and stability could be al-
tered in diabetic patients [23,24]. Efficient wound healing mechanisms are important to
maintain transparency and restore the barrier function of the cornea. The use of topical
anti-inflammatory medications is useful for alleviating ocular surface inflammation and
promoting re-epithelialization [20].
Contact lenses (CLs) are being positioned as advantageous platforms for the sustained
release of ophthalmic drugs [25–27]. Once applied to the eye, the CL may release the drug
toward the post-lens tear film, which has slower turnover than the lachrymal fluid in the
absence of the lens. Prolonged permanence and higher drug levels on the ocular surface
facilitate drug penetration into eye tissues [28–30]. Despite the therapeutic advantages
of medicated CLs, their design is still a huge challenge because most available CLs lack
affinity for ophthalmic drugs [31]. This problem can be overcome by means of bioinspired
strategies that rely on mimicking the human pharmacological receptor of the drug into
the CL structure [28]. The incorporation of functional monomers bearing chemical groups
similar to those present in the natural drug binding site, and their arrangement assisted
by molecular imprinting has been shown useful to improve the performance of CLs as
platforms for the sustained release of acetazolamide and ethoxzolamide [32], ketotifen
fumarate [30], olopatadine [33], epalrestat [34], naltrexone [35], transferulic acid [36], etc.
This bioinspired strategy does not compromise the performance of CLs as medical devices
for vision correction.
The present work relies on the hypothesis that hydrogels that can mimic the compo-
nents of the active site of HMG–CoA reductase might exhibit enhanced affinity for statins.
Thus, the aim of the work was to design, for first time, atorvastatin-loaded CLs using
functional monomers that bear chemical groups that resemble those present in HMG–CoA
reductase and that can be successfully integrated with the CL network in order to optimize
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the loading and release of atorvastatin calcium while still preserving the properties required
for CLs, mainly in terms of ocular tolerance, light transmission, and mechanical properties.
Statins have a polar head group that mimics the natural substrate of HMG–CoA reductase
and, thus, bind the active site, blocking the access of the natural substrate. In the binding of
type II statins (as atorvastatin), the isopropyl group participates in Van der Waals contacts
with the enzyme involving residues Leu562, Val683, Leu853, Ala856, and Leu857. Atorvastatin
(Figure 1A) forms a hydrogen bond through its carbonyl oxygen atom with Ser565, while the
fluorophenyl group can coordinate to Arg590 through polar interactions [37]. Taking into
account the functionalities of the amino acids involved in the binding site of HMG–CoA
reductase, ethylene glycol phenyl ether methacrylate (EGPEM), 2-aminoethyl methacrylate
hydrochloride (AEMA), and N-(3-aminopropyl) methacrylamide hydrochloride (APMA)
(Figure 1) were chosen as functional monomers after a first screening of the interaction
with atorvastatin using computational modeling. Hydrogels were prepared from mixtures
of 2-hydroxyethyl methacrylate (HEMA), EGPEM, AEMA, and APMA at various ratios
(Table 1). Some hydrogels were synthesized in the presence of the drug (imprinted hydro-
gels) to verify whether the drug molecules could contribute to a better arrangement of the
monomers for a more efficient formation of ad hoc artificial receptors.
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Figure 1. Structure of atorvastatin alcium (A) and the functional monomers used to synthesize the
hydrogels: (B) 2-aminoethyl methacrylate hydrochloride (AEMA); (C) N-(3-aminopropyl) methacry-
lamide hydrochloride (APMA); and (D) ethylene glycol phenyl ether methacrylate (EGPEM), and (E)
2-hydroxyethyl methacrylate (HEMA).
Table 1. Composition of the monomer mixtures used to synthesize the hydrogels. ni: nonimprinted; i: imprinted.
Hydrogel Code HEMA (mL) EGDMA (µL) EGPEM (µL) AEMA (mg) APMA (mg) torvastatin (mg) I (mg)
AF1 3 12.10 - - - - 4.93
AF1ni 3 12.10 - - - - 4.93
AF1i 3 12.10 - - - 12.57 4.93
AF2 3 12.10 112.50 - - - 4.93
AF2ni 3 12.10 17.18 - - - 4.93
AF2i 3 12.10 17.18 - - 12.57 4.93
AF3 3 12.10 112.50 9.90 - - 4.93
AF3ni 3 12.10 17.18 14.91 - - 4.93
AF3i 3 12.10 17.18 14.91 - 12.57 4.93
AF4 3 12.10 112.50 - 21.45 - 4.93
AF4ni 3 12.10 17.18 - 16.08 - 4.93
AF4i 3 12.10 17.18 - 16.08 12.57 4.93
AF5 3 12.10 - 19.90 - - 4.93
AF5ni 3 12.10 - 14.91 - - 4.93
AF5i 3 12.10 - 14.91 - 12.57 4.93
AF6 3 12.10 - - 21.45 - 4.93
AF6ni 3 12.10 - - 16.08 - 4.93
AF6i 3 12.10 - - 16.08 12.57 4.93
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Since sterilization is a mandatory step in the conditioning of CLs and may affect the
material properties, the drug stability, and the drug release pattern, a relevant second aim
of the present work was to evaluate to what extent several sterilization techniques may alter
the capability of the designed CLs to act as platforms for atorvastatin release. The stability
of the hydrogels and the drug in separate and of the drug-loaded hydrogels against steam
heat (autoclave), gamma radiation, and high hydrostatic pressure (HHP) techniques was
evaluated. Steam heat and gamma radiation are the most used methods for sterilization of
medical devices [38]. Steam heat is efficient, fast, and does not involve toxic agents, but it
is not suitable for materials and drugs that are heat sensitive [39]. Gamma radiation allows
operating at low temperatures, but it is expensive, complex, and may affect the polymer
properties [40]. HHP is increasingly used in the food industry to inactivate microorganisms
without altering the food properties [41,42]. Pressure-based methods are also used for the
disinfection of biomaterials and for vaccine production [42]. Furthermore, according to
previous reports [43], HHP seems to be an alternative method for terminal sterilization of
drug-loaded intraocular lenses.
Finally, the most promising CLs were evaluated regarding cytocompatibility with
Balb/3T3 fibroblasts, ocular tolerance (HET–CAM), and ex vivo accumulation/permeability
of atorvastatin into/through the porcine cornea and sclera tissues.
2. Materials and Methods
2.1. Materials
Atorvastatin calcium was from Biosynth (Compton, UK). 2-Hydroxyethyl methacry-
late (HEMA) was supplied by Merck (Darmstadt, Germany). Ethylene glycol dimethacry-
late (EGDMA), ethylene glycol phenyl ether methacrylate (EGPEM), 2,2′-azo-
bis(isobutyronitrile) (AIBN), 2-aminoethyl methacrylate hydrochloride (AEMA), and
dichlorodimethylsilane were from Sigma-Aldrich (Steinheim, Germany). N-(3-aminopropyl)
methacrylamide hydrochloride (APMA) was from PolySciences Inc. (Warrington, PA, USA).
Sodium chloride (NaCl) was from Scharlau (Barcelona, Spain), and ethanol absolute was
from VWR Chemicals (Leuven, Belgium). Ultrapure water (resistivity > 18.2 MΩ cm;
Milli-Q®, Millipore Ibérica, Madrid, Spain) was obtained by reverse osmosis. Simulated
lachrymal fluid (SLF) was prepared with the following composition in water: 6.78 g/L
NaCl from Scharlau (Barcelona, Spain), 1.90 g/L NaHCO3 from Probus (Barcelona, Spain),
1.38 g/L KCl, and 0.042 g/L CaCl2 from Merck (Darmstadt, Germany) with pH 7.4 [23].
Carbonate buffer pH 7.2 was prepared by mixing two buffer solutions: buffer solution A
(100 mL: 1.24 g NaCl, 0.071 g KCl, 0.02 g NaH2PO4 from Merck (Darmstadt, Germany),
0.49 g NaHCO3) and buffer solution B (100 mL: 0.023 g CaCl2, 0.031 g MgCl2 from Pan-
reac (Barcelona, Spain)). Balb/3T3 fibroblasts were provided by American Type Culture
Collection (Manassas, VA, USA).
2.2. Computational Modeling
The 3D structure of the functional monomers (EGPEM, AEMA, and APMA) and
atorvastatin calcium was taken from the PubChem database [44]. The Autodock Tools
version 4.2.6 software (Molecular Graphics Lab., La Jolla, CA, USA) was used to perform
computational molecular docking in two steps, using a semiempirical free energy force
field. The molecules under study, the ligand (in this case, the monomer) and the receptor
(drug) started in an unbound conformation, and after that, the intramolecular energetics
were estimated from these unbound states to the conformation in the bound state. Then, the
intermolecular energetics of their bound conformation were analyzed using the Lamarckian
genetic algorithm [45]. Finally, estimated free energy of binding (∆Gbinding) and dissociation
constant (Ki) values were obtained [46]. In all cases, the grid was generated with default
settings around the monomer and the drug.
Pharmaceutics 2021, 13, 606 5 of 22
2.3. Hydrogel Preparation
Compositions of the monomers’ mixtures and the amounts of atorvastatin calcium
added are shown in Table 1. The hydrogels were designed with AF codes, followed by
a number referring to a specific combination of monomers and one/two letters, which
indicate whether the networks were imprinted (letter i) or not (letters ni). The components
were mixed under magnetic stirring (400 rpm) for 120 min and then 5 min in sonication.
AIBN (initiator) was added, and the solutions were magnetically stirred again (100 rpm)
for 10 min. Finally, the solutions were injected into molds made from two glass plates
(10 × 10 cm) previously treated with dichlorodimethylsilane and separated by a silicone
frame (0.3 mm thickness) [47]. The polymerization was carried out by heating at 50 ◦C
for 12 h, then the temperature was raised to 70 ◦C, and the polymerization was continued
for a further 24 h. In such a way controlled thermal decomposition of the initiator AIBN
prevented nitrogen bubbles formation [48].
After polymerization, each hydrogel was immersed in boiling water (1000 mL) for
15 min to remove unreacted monomers and to facilitate the cut as 10 mm discs. The
hydrogels were washed in ultrapure water for 24 h replacing the medium twice a day and
then 0.9% NaCl and in water, every other day, replacing the medium twice a day for 10 days.
During the cleaning process, the medium was kept under magnetic stirring (200 rpm) at
room temperature and protected from the light. The cleaning process was monitored
spectrophotometrically (Agilent 8453, Waldbronn, Germany) for both residual monomers
leakage (only observed in the first washing solutions) and quantification of the amount
of atorvastatin extracted. Atorvastatin was quantified from absorbance measurements at
242 nm using a validated calibration curve prepared for drug solutions in ethanol:water
(20:80 v/v). Finally, the discs were dried at 70 ◦C for 24 h.
2.4. Hydrogel Characterization
Solvent uptake. Dried hydrogel discs were weighed (W0) and immersed in SLF or
atorvastatin calcium solution (0.04 mg/mL in ethanol:water 20:80 v/v) for 24 h at room
temperature. Four replicates were tested for each hydrogel type. At a pre-established time
(0.5, 1, 1.5, 2, 3, 4, 5, 6, and 24 h), the discs were removed, carefully wiped, and weighed
(Wt). The solvent uptake was monitored as the increase in weight with respect to the dried
disc as the following equation:
Solvent uptake (%) = [(W0 −Wt)/W0] × 100 (1)
Light transmission. The transmittance of discs hydrated in SLF and atorvastatin
calcium solution (0.04 mg/mL in ethanol:water 20:80 v/v) was recorded, in quadruplicate,
in 200–800 nm range (UV–Vis spectrophotometer, Agilent 8453, Boeblingen, Germany).
Mechanical properties. The mechanical properties of hydrated hydrogels (in 0.9%
NaCl) were evaluated through tensile tests using a TA.XT Express Texture Analyser (Stable
Micro Systems, Godalming, UK), with a 0.005 N trigger force, 50 N load cell, and test speed
of 0.25 mm/s. Each hydrogel was cut with a dog bone-shaped mold (total 18 × 5 mm,
in the center 6 × 2.5 mm). The samples were fixed to the upper and lower clamps. The
Young’s modulus was determined from the initial slope of the obtained stress–strain curves.
Five independent experiments were conducted for each hydrogel formulation, before and
after the different sterilization methods.
2.5. Atorvastatin Loading and Release
Nonimprinted and imprinted dried discs, in quadruplicate, were weighed (approx.
20 mg) and immersed in vials containing 10 mL of atorvastatin calcium solution (0.04 mg/mL
in ethanol:water 20:80 v/v). The vials were kept under magnetic stirring (150 rpm) at room
temperature and protected from the light for 48 h. At pre-established periods of time, the
absorbance of the loading solution was measured by UV spectrophotometry (Agilent 8453,
Boeblingen, Germany) at 242 nm and the amount of atorvastatin loaded was calculated
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as the difference between the initial and final amount of drug in the solution. The net-
work/water partition coefficient of atorvastatin, KN/W, was estimated for each hydrogel
type from the total amount loaded as follows [49]:
Amount loaded = [(Vs + KN/W × Vp)/Wp] × C0 (2)
In this equation, Vs is the volume of solution absorbed by the hydrogel, Vp the dried
polymer volume, Wp the dried hydrogel weight, and C0 the drug concentration in the
loading solution.
Atorvastatin-loaded discs were rinsed with SLF and the discs were placed in vials
with 10 mL of SLF (pH = 7.4, similar to the precorneal film [50]) at 37 ◦C and magnetically
stirred at 150 rpm. The vials were protected from the light. Samples of the medium
(3 mL) were periodically withdrawn and returned to the vial immediately after absorbance
measurement at 242 nm. After 8 h and until the end of the test, samples of the release
medium (2 mL) were withdrawn and replaced with the same volume of fresh SLF to
maintain sink conditions and avoid false plateaus.
2.6. HET–CAM Test
The hen’s egg test chorioallantoic membrane (HET–CAM) assay was used for prelimi-
nary screening of ocular irritancy of the hydrogels according to the ICCVAM protocol [51],
as previously described [34]. Briefly, fertilized hen’s eggs (Coren, San Cibrao das Viñas,
Spain) were incubated at 37 ◦C with 60% relative humidity for 7 days and were manually
rotated 180◦ three times a day for the duration of the incubation. On the eighth day, the
eggs were cut on the wider extreme to extract the eggshell, remove the inner membrane,
and expose the chorioallantoic membrane (CAM). Atorvastatin-loaded hydrogel discs and
300 µL of atorvastatin calcium (0.04 mg/mL in ethanol:water 20:80 v/v) were carefully
placed on the CAM and the possible hemorrhage, vascular lysis, or coagulation of the
vessels were monitored for 5 min. Two independent experiments were carried out for
each hydrogel and the drug solution. The discs were previously loaded with atorvastatin
calcium for 48 h, as described above. NaCl (0.9%) and NaOH (0.1 N) solutions were used
as negative and positive controls, respectively. Then, the irritation score (IS) was estimated,
as previously reported [35].
2.7. Sterilization
Three different sterilization protocols were tested for hydrogels previously swollen in
NaCl 0.9% for at least 24 h or in drug solution (0.04 mg/mL) for 48 h and maintained in
the same solutions: (i) steam heat (SH) sterilization for 1 h using an autoclave (Uniclave
88/75L; A.J. Costa, Cacém, Portugal) at 121 ◦C and 1 bar [43,52]; (ii) gamma-radiation
(GI) sterilization with 25 kGy radiation dose [53] and a dose rate of ≈5 kGy/h at room
temperature (only for the hydrogels without drug); and (iii) high hydrostatic pressure
(HHP) at 70 ◦C and 600 MPa for 10 min [43]. Four independent experiments were carried
out for each hydrogel and sterilization condition. For the HHP, each hydrogel disc was
previously packed and sealed in polyamide/polyethylene vacuum bags filled with NaCl
0.9% or drug solution and preheated at 70 ◦C for 10 min. Then, the bags were placed inside
a polytetrafluoroethylene insulation vessel prefilled with water at the same temperature
and immediately pressurized in a Hiperbaric 55 equipment (Burgos, Spain) [54].
Aliquots of the drug solution (0.02 mg/mL in ethanol:water 20:80 v/v) were ster-
ilized under the same conditions as the hydrogels and thereafter analyzed by UV–Vis
spectrophotometry and HPLC (as described in Section 2.10).
After the sterilization processes, the mechanical properties of fully hydrated hydrogels
(in NaCl 0.9%) previously equilibrated at room temperature were evaluated. Furthermore,
the loading and release experiments were carried out again with the discs sterilized in
NaCl 0.9% medium and that were washed in water for 24 h and dried at 70 ◦C for another
24 h under the same conditions as described above (Section 2.5).
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2.8. FTIR–ATR Analysis
The FTIR-attenuated total reflectance (ATR) spectra of the nonsterilized and sterilized
AF1, AF6, AF6ni, and AF6i hydrogels (after steam heat, gamma radiation, and high
hydrostatic pressure) were recorded in an FTIR Varian 670-IR equipped with a PIKE
GladiATR Diamond Crystal Attenuated Total Reflectance accessory with a resolution of
4 cm−1 and 64 scans.
2.9. Cytocompatibility Studies
Nonloaded and loaded hydrogels (AF6, AF6ni, and AF6i) were evaluated against
Balb/3T3 fibroblasts cells (ATCC CCL-163; Manassas, VA, USA). Hydrogels (10 mm in
diameter; approx. 20 mg) were loaded for 48 h in an atorvastatin solution (0.04 mg/mL in
ethanol:water 20:80 v/v) or immersed in 0.9% NaCl solution (nonloaded hydrogels), cut in
four symmetric pieces, and sterilized by HHP at 70 ◦C and 600 MPa for 10 min. Balb/3T3
cells were cultured in T75 flasks using Dulbecco’s modified Eagle medium (DMEM; Fisher
Scientific, Newington, NH, USA) supplemented with 10% fetal bovine serum and 1%
antibiotics (10,000 U/mL penicillin and 10,000 µg/mL streptomycin) in an incubator at
37 ◦C and 5% CO2. Then, cells were detached from the flasks at 80% confluence using
TrypLE® (Sigma Aldrich, St. Louis, MO, USA). Suspended cells were counted, seeded
in wells of 96-well plates (20,000 cells/well), and allowed to attach for 24 h. Pieces (five)
of discs were then placed individually in contact with the cells incubated for 24 h. Cells
incubated in culture medium (negative control) and cells incubated in medium containing
atorvastatin (0.04 and 0.02 mg/mL) were also evaluated.
The viability of the cells was evaluated using a Cell Counting kit-8 (CCK-8; Dojindo
Molecular Technologies, Rockville, MD, USA) following the instructions from the manu-
facturer. Briefly, samples and culture medium were removed from the wells and 200 µL
of a CCK-8 working solution (10 % v/v CCK-8 reagent in complete culture medium) were
added to each well and incubated for 1 h at 37 ◦C. Finally, absorbance was measured at
450 nm (UV Bio-Rad Model 680 microplate reader, Hercules, CA, USA), and cell viability
(%) was calculated as follows.
Cell viability (%) = (Abs exp/Abs negative control) × 100 (3)
2.10. Cornea and Sclera Permeability and Accumulation
Ex vivo permeability assays were carried out, in triplicate, with nonsterilized AF6,
AF6ni, and AF6i loaded hydrogels following the BCOP test protocol, as previously de-
scribed [55,56]. Porcine eyes were collected from a local slaughterhouse in the first hour
after death and transported completely immersed in PBS solution in an ice bath. Corneas
and scleras were isolated using a scalpel, washed with PBS, and mounted in vertical dif-
fusion (Franz) cells. The donor and receptor chambers were filled with carbonate buffer
pH 7.2 and maintained in a bath at 37 ◦C, gentle magnetic stirring. After 30 min, the
solution in the donor chamber was completely removed using a Pasteur pipette and the
corneas and scleras were exposed for 6 h to atorvastatin-loaded discs (AF6, AF6ni, and
AF6i discs with 2 mL of SLF) or to control atorvastatin solution (60 µg/mL in ethanol:water
20:80 v/v, 1 mL). The donor chambers were covered with parafilm to prevent evaporation.
Samples (1 mL) were removed from the receptor chamber at 0.5, 1, 2, 3, 4, 5, and 6 h,
replacing with the same volume of fresh carbonate buffer each time and taking care of
removing air bubbles from the diffusion cell.
The amount of atorvastatin in the receptor medium samples was quantified by HPLC
(AS-4140 Autosampler, PU-4180 Pump, LC-NetII/ADC Interface Box, CO-4060 Column
Oven, MD-4010 Photodiode Array Detector, JASCO, Tokyo, Japan) fitted with a C18 column
(Waters Symmetry C18, 5 µm, 4.6 × 250 mm) and operated with ChromNAV software
v.2. Mobile phase consisted of methanol: 0.05 M sodium phosphate (NaH2PO4) buffer
(70:30 v/v, pH adjusted to 4.1 with o-phosphoric acid) at 1.00 mL/min and 25 ◦C [57]. The
injection volume was 50 µL, and the total run time of each sample was 10 min. Atorvastatin
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was quantified at 247 nm (retention time of 6.3 min). The HPLC method was validated
using two different calibration curves of atorvastatin in carbonate buffer, one between
0.125–2 µg/mL and the other one 2–16 µg/mL. The limit of detection (LOD) and limit of
quantification (LOQ) values were 0.05 and 0.125 µg/mL, respectively.
After 6 h of experiment, the discs and solutions were removed from the donor cham-
bers. The corneas and scleras were also removed from the diffusion cells and rinsed with
0.9% NaCl and immersed in 3 mL of ethanol:water (50:50 v/v) overnight at 37 ◦C under
magnetic stirring. Then, they were sonicated for 99 min at 37 ◦C, centrifuged (1000 rpm,
5 min, 25 ◦C), and the supernatant filtered (Scharlau® Syringe Filter, 0.22 µm 13 mm PTFE
hydrophilic), centrifuged again (14,000 rpm, 20 min, 25 ◦C), and filtered to be measured by
HPLC, as explained above.
2.11. Light Stability of Atorvastatin Calcium Solution
Solutions of atorvastatin calcium (0.02 mg/mL in ethanol:water 20:80 v/v) were placed
in quartz cells (2 mL per cell) and exposed to fluorescent tube light (F8T5 Daylight, 6500 K,
HITACHI) for 8 h at room temperature. The experiments were carried out in duplicate.
UV–Vis spectra and HPLC chromatograms were recorded before and after exposition.
2.12. Statistical Analysis
Statistical analysis was performed using SPSS v.26.0 (IBM Co., Armonk, NY, USA).
The descriptive data are presented as mean ± standard deviation. The normality of all
variables was evaluated using the Shapiro–Wilk test. If normality was respected, a paired-
samples t-test was used to compare the means between the two groups. One-way analysis
of variance was used to compare the means of more than two groups. If normality was
not verified, nonparametric tests were performed using Kruskal−Wallis test with post hoc
Games–Howell correction. The level of significance used was 0.05.
3. Results and Discussion
3.1. Hydrogels Synthesis and Conditioning
The intensity of the interactions between atorvastatin calcium and the functional
monomers was preliminary assessed using computer-assisted molecular modeling, which
is considered as a green screening strategy for the rational selection of the composi-
tion [58,59]. The estimated free energy of the binding, inhibition constant, and the most
probable structure are shown in Figure 2. Atorvastatin interacted with the structural
monomer (HEMA) through a hydrogen bond between the hydrogen atom of the hy-
droxyl group and the carbonyl group of atorvastatin. Atorvastatin interacted with EGPEM
through a hydrogen bond between the N atom of the amido group of atorvastatin and
the oxygen ether group of EGPEM, stabilized through π–π stacking of the benzyl groups
of both molecules. In the case of AEMA and APMA, the interaction occurred between
the amino group of these monomers and the carboxylic acid group of atorvastatin. The
interaction of the drug with APMA was remarkably more favorable both in terms of bind-
ing energy (∆Gbinding) and stability against dissociation (Ki). The interaction with the two
other monomers, EGPEM and AEMA, was thermodynamically weaker but still favorable.
Therefore, the three functional monomers were investigated regarding their capability to
endow the hydrogels with an affinity for atorvastatin. It should be noted that the ∆Gbinding
values, although small, are in the same order of magnitude as those reported for other
functional monomer:template 1:1 interactions using similar computational modeling soft-
ware [60,61]. The binding enthalpy reported for HMG–CoA reductase and atorvastatin
calcium in microcalorimetry titration experiments was higher (−10.9 Kcal/mol) but still in
a comparable range [62].
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estimated free energy of the binding and inhibition constant. In the structures, N atoms are shown in blue, oxygen atoms in
red, and the main bond interaction is shown in green.
Sets of hydrogels were prepared by combining AEMA, APMA, and EGPEM at various
proportions as summarized in Table 1. AF1, AF1ni, and AF1i hydrogels were prepared
without any functional monomer to be used as control. The first set of hydrogels AF2–AF6
was prepared with a concentration of APMA or AEMA of 40 mM and EGPEM of 200 mM.
All monomers dissolved rapidly in HEMA medium with the exception of AEMA, and
therefore AF3 and AF5 did not incorporate all feed AEMA content. Therefore, the second
set of nonimprinted (AF1ni–AF6ni) and imprinted (AF1i–AF6i) hydrogels were prepared
with lower concentrations of functional monomers (30 mM). Atorvastatin dissolved easily
in the monomer solutions. Atorvastatin amount corresponded to drug:functional monomer
1:4 molar ratio. After polymerization, the hydrogel sheets were boiled in distilled water,
which is the typical cleaning process of soft CLs after fabrication. Then, the hydrogels were
successively immersed in water and NaCl 0.9% for the complete removal of atorvastatin
before loading assay. Cleaning with NaCl 0.9% solution was needed to weaken the ionic
Pharmaceutics 2021, 13, 606 10 of 22
interactions of atorvastatin with the hydrogels prepared with AEMA and APMA, as
previously observed for other HEMA-based hydrogels [63]. The removal process was
monitored spectrophotometrically at 242 nm until no leakage of drug or monomers was
recorded.
3.2. Hydrogels Characterization
Dried discs rapidly sorbed SLF (Figure 3) and the equilibrium was reached in one hour.
The hydrogels prepared with the highest amount of EGPEM (AF2, AF3, and AF4) presented
the lowest solvent uptake either in SLF or atorvastatin calcium solution because of the
hydrophobicity of this monomer. Imprinted and nonimprinted hydrogels presented similar
solvent uptake values. The solvent uptake in atorvastatin solution was significantly higher
than that recorded in SLF, about 90% due to the addition of ethanol. Organic solvents
as ethanol increase the solubility of the hydrophobic moieties of PHEMA in the aqueous
medium, promoting hydrogel swelling [64]. Regarding light transmission, all hydrated
hydrogels were transparent in the visible range (400–700 nm), with transmittance values
close to or above 90% (Figure S1 in Supplementary Materials) [65]. The presence of the
drug did not alter the transmittance in the visible region.
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Figure 3. Solvent uptake (%) in (A) simulated lachrymal fluid and (B) atorvastatin calcium solution (0.04 mg/mL in eth-
anol:water 20:80 v/v) for all hydrogels before sterilization. Codes as in Table 1 (n = 4; mean values and standard devia-
tions). 
3.3. Atorvastatin Loading and Release 
Hydrogel discs were dried and immersed in atorvastatin solution (0.04 mg/mL in 
ethanol:water 20:80 v/v) to quantify the drug loading ability (Figure 4). Nonfunctional-
ized hydrogels did not uptake any atorvastatin (AF1, AF1ni, and AF1i). Predictably, the 
amount of atorvastatin loaded increased with the content in APMA and AEMA func-
tional monomers. The hydrogels with larger content in functional monomers required 
more than 24 h to complete the sorption, while the other nonimprinted and imprinted 
hydrogels completed the loading in the first 8 h. Addition of EGPEM did not further 
improve the loading (code AF2). The uptake was remarkably higher for hydrogels pre-
pared with APMA (AF4, AF6, AF4ni, AF6ni, AF4i, and AF6i), which had the highest af-
Figure 3. Solvent uptake (%) in (A) simulated lachrymal fluid and (B) atorvastatin calcium solution (0.04 mg/mL in
ethanol:water 20:80 v/v) for all hydrogels before sterilization. Codes as in Table 1 (n = 4; mean values and standard
deviations).
3.3. Atorvastatin Loading and Release
Hydrogel discs were dried and im ersed in atorvasta in solution (0. 4 mg/mL in
ethanol:water 20:80 v/v) to quantify the drug loading ability (Figure 4). Nonfunctional-
ized hydrogels did not uptake any atorvastatin (AF1, AF1ni, and AF1i). Predictably, the
amount of atorvastatin loade increased with the content in APM and AEM functional
monomers. The hydrogels with larger content in functional monomers required more than
24 h to complete the sorption, while the other nonimprinted and imprinted hydrogels com-
pleted the loading in the first 8 h. Addition of EGPEM did not further improve the loading
(code AF2). The uptake was remarkably higher for hydrogels prepared with APMA (AF4,
AF6, AF4ni, AF6ni, AF4i, and AF6i), which had the highest affinity for atorvastatin. Im-
printed hydrogels showed minor increases in the amount of atorvastatin loaded compared
to nonimprinted ones, which is typical of drugs in which one-point interaction prevails
over other feasible interactions [66].
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orded, except for AF6ni and AF6i (p < 0.05). The KN/W values of atorvastatin recorded for 
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Figure 4. Atorvastatin loading profiles of all hydrogels ((A) first set of hydrogels; (B) nonimprinted hydrogels and (C)
imprinted hydrogels) soaked in 10 mL of atorvastatin solution (0.04 mg/mL in ethanol:water 20:80 v/v) at room temperature
under magnetic stirring (150 rpm) for 48 h. Hydrogel codes as in Table 1 (n = 4; mean values and standard deviations).
Compared to nonfunctionalized hydrogel (AF1) and EGPEM hydrogels (AF2), hydro-
gels bearing AEMA or APMA hydrogels showed two orders of magnitude greater KN/W
values (Table 2). The highest KN/W values were recorded for hydrogels with the largest
content in functional monomers. APMA hydrogels (AF4 and AF6) had statically significant
higher (p < 0.05) KN/W values than AEMA hydrogels (AF3 and AF5), in good agreement
with the computational modeling analysis. Comparing the imprinted and nonimprinted
hydrogels, no statistically significant differences in KN/W values were recorded, except
for AF6ni and AF6i (p < 0.05). The KN/W values of atorvastatin recorded for hydrogels
prepared with AEMA or APMA were higher than those previously found for function-
alized CL design to uptake other drugs such as naltrexone [35], polymyxin B [67],
acetazolamid , ethoxzolamide [32], or f rulic acid [36]. High KN/W values can be typically
found for drugs that can estab ish strong ionic interactions with the hydrogel moieties, as
observed for epalrestat and APMA-functionalized networks [34].
Table 2. Amounts of atorvastatin loaded by each hydrogel, and the KN/W values calculated (mean
value and in parenthesis standard deviations). Codes as in Table 1.
Hydrogel Code Amount of Atorvastatin Loaded (mg/g) KN/W
AF1 0.11 (0.08) 2.1 (2.3)
AF1ni 0.17 (0.20) 3.9 (6.2)
AF1i 0.18 (0.21) 4.1 (6.3)
AF2 0.09 (0.04) 1.7 (1.1)
AF2ni 0.16 (0.21) 3.4 (6.3)
AF2i 0.16 (0.21) 3.4 (5.6)
AF3 7.12 (0.38) 177.6 (11.6)
AF3ni 5.66 (0.12) 140.9 (3.0)
AF3i 5.22 (0.69) 130.1 (17.1)
AF4 11.32 (0.18) 282.6 (5.5)
AF4ni 6.31 (0.21) 157.2 (6.5)
AF4i 6.77 (0.27) 168.7 (6.6)
AF5 7.50 (0.28) 187.0 (8.6)
AF5ni 4.69 (0.35) 116.7 (10.7)
AF5i 5.00 (0.15) 124.6 (4.7)
AF6 11.08 (0.63) 276.4 (19.2)
AF6ni 5.81 (0.12) 144.7 (3.5)
AF6i 6.69 (0.23) 166.7 (7.0)
Pharmaceutics 2021, 13, 606 12 of 22
Atorvastatin-loaded discs were rinsed with water and immersed in 10 mL of SLF at
37 ◦C (sink conditions). The vials were maintained under oscillatory movement (150 rpm)
to avoid the formation of a boundary layer around the discs, which could delay the release
and lead to false sustained release [68]. The hydrogels prepared with the largest contents in
functional monomers showed release patterns (Figure 5) similar to those recorded for less
functionalized hydrogels when plotted as percentage released (Figure S2 in Supplementary
Materials). Relevantly, all hydrogels provided sustained release almost for one week,
covering extended wear of CL. The Higuchi equation was fitted quite well to the release
profiles, indicating that drug diffusion through the swollen network is the main mechanism
regulating the release [34] (Table S1 in Supplementary Materials).
Pharmaceutics 2021, 13, x FOR PEER REVIEW 12 of 23 
 
 
Table 2. Amounts of atorvastatin loaded by each hydrogel, and the KN/W values calculated (mean 
value and in parenthesis standard deviations). Codes as in Table 1. 
Hydrogel Code Amount of Atorvastatin 
Loaded (mg/g) 
KN/W 
AF1 0.11 (0.08) 2.1 (2.3) 
AF1ni 0.17 (0.20) 3.9 (6.2) 
AF1i 0.18 (0.21) 4.1 (6.3) 
AF2 0.09 (0.04) 1.7 (1.1) 
AF2ni 0.16 (0.21) 3.4 (6.3) 
AF2i 0.16 (0.21) 3.4 (5.6) 
AF3 7.12 (0.38) 177.6 (11.6) 
AF3ni 5.66 (0.12) 140.9 (3.0) 
AF3i 5.22 (0.69) 130.1 (17.1) 
AF4 11.32 (0.18) 282.6 (5.5) 
AF4ni 6.31 (0.21) 157.2 (6.5) 
AF4i 6.77 (0.27) 168.7 (6.6) 
AF5 7.50 (0.28) 187.0 (8.6) 
AF5ni 4.69 (0.35) 116.7 (10.7) 
AF5i 5.00 (0.15) 124.6 (4.7) 
AF6 11.08 (0.63) 276.4 (19.2) 
AF6ni 5.81 (0.12) 144.7 (3.5) 
AF6i 6.69 (0.23) 166.7 (7.0) 
Atorvastatin-loaded discs were rinsed with water and immersed in 10 mL of SLF at 
37 °C (sink conditions). The vials were maintained under oscillatory movement (150 rpm) 
to avoid the formation of a boundary layer around the discs, which could delay the re-
lease and lead to false sustained release [68]. The hydrogels prepared with the largest 
contents in functional monomers showed release patterns (Figure 5) similar to those 
recorded for less functionalized hydrogels when plotted as percentage released (Figure 
S2 in Supplementary Materials). Relevantly, all hydrogels provided sustained release 
almost for one week, coveri g extended wear of CL. The Higuchi equation was fitted 
quit  well to the release profiles, indicating that drug diffusion thr ugh the swollen 
network is the main mechanism r gulating the release [34] (Table S1 in Supplem nt ry 
Materials). 
Time (hours)



























































Figure 5. Atorvastatin release profiles from drug-loaded discs ((A) first set of hydrogels; (B) nonimprinted hydrogels and 
(C) imprinted hydrogels) in SLF at 37 °C under magnetic stirring (150 rpm). Codes as in Table 1 (n = 4; mean values and 
standard deviations). 
i r . t r st ti r l s r fil s fr r -l iscs (( ) first s t f r ls; ( ) i ri t r ls
(C) imprinted hydrogels) in SLF at 37 ◦C under magnetic stirring (150 rpm). Codes as in Table 1 (n = 4; mean values and
standard deviations).
3.4. HET–CAM Test and Cytocompatibility
The hen’s egg test on the chorioallantoic membrane is a fast and sensitive procedure
that provides useful preliminary information about ocular irritancy and may be a validated
alternative to the low volume eye test scale developed for rabbits [69]. The CAM tissue
of fertilized hen eggs is noninnervated and contains arteries, veins, and capillaries that
respond to injury in an analog way to ocular conjunctiva [70]. Images of CAM after 5 min
exposure to atorvastatin calcium solution (300 µL, 0.04 mg/mL in ethanol:water 20:80 v/v)
and atorvastatin-loaded discs showed no damages, as occurred for the negative control
(NaCl 0.9%) (Figure S3 in Supplementary Materials). The presence of small contents of
ethanol in the drug loading solution and in the atorvastatin-loaded hydrogels did not
cause irritation, as previously reported for formulations containing up to 33% ethanol [71].
Differently, the positive control (NaOH 0.1 N) caused an irritation score (IS) of 18.82.
Therefore, all formulations can be considered as nonirritant for the ocular surface.
The cytotoxicity of the sterilized hydrogels (nonloaded and loaded with atorvas-
tatin) was assessed through exposure to Balb/3T3 cells (Figure 6). The loading solution
(0.04 mg/mL) and a solution containing the maximum amount of atorvastatin loaded by
the hydrogels after 48 h (0.02 mg/mL) were also evaluated. In all cases, cell viability was
above 90%. Overall, the designed hydrogels did not produce cytotoxic effects and could be
safely used as biomaterials suitable for contact lenses, according to ISO 10993-5:2009 [72].
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3.5. Effects of Sterilization 
Sterilization of CLs is usually carried out by steam heat (autoclave) or gamma radi-
ation [73]. Sterilization becomes a big challenge for drug-loaded CLs because it may 
compromise the stability of the drug or impact negatively on the drug release profile [43]. 
In the present work, steam heat, gamma radiation, and HHP were tested in order to 
evaluate their effects on the material properties and on their subsequent capability to 
load atorvastatin and control drug release. First, hydrogels were sterilized while im-
mersed in a NaCl solution, and the elastic modulus was evaluated (Figure 7). Steam heat 
sterilization did not significantly affect the elastic modulus of any hydrogel (Kruskal–
Wallis test, p > 0.05). Differently, gamma radiation significantly decreased the elastic 














































Figure 6. Viability of Balb/3T3 cells (%; mean and standard deviations) determined by CCK-8 assay,
after 24 h exposure to nonloaded (NL), and atorvastatin loaded (L) hydrogels (AF6, AF6ni and AF6i)
and two atorvastatin solutions (At; 0.04 and 0.02 mg/mL in ethanol:water 20:80 v/v). Negative control
(C-) cells cultured in the absence of any treatment. Dashed line corresponds to 70% cell viability.
3.5. Effects of Sterilization
Sterilization of CLs is usually carried out by steam heat (autoclave) or gamma ra-
diation [73]. Sterilization becomes a big challenge for drug-loaded CLs because it may
compromise the stability of the drug or impact negatively on the drug release profile [43]. In
the present work, steam heat, gamma radiation, and HHP were tested in order to evaluate
their effects on the material properties and on their subsequent capability to load atorvas-
tatin and control drug release. First, hydrogels were sterilized while immersed in a NaCl
solution, and the elastic modulus was evaluated (Figure 7). Steam heat sterilization did
not significantly affect the elastic modulus of any hydrogel (Kruskal–Wallis test, p > 0.05).
Differently, gamma radiation significantly decreased the elastic modulus value of AF1ni,
AF2ni, AF3ni, AF4ni, AF5ni, AF6ni, AF3i, and AF5i hydrogels (Kruskal–Wallis test, p < 0.05).
HHP sterilization increased significantly the elastic modulus to 0.87 ± 0.02 MPa for AF4
and 0.79± 0.0 for AF6 (Kruskal–Wallis test, p < 0.05). Nevertheless, in all cases, the changes
were small in magnitude and the elastic modulus obtained of the sterilized hydrogels
(0.61–1.04 MPa) remained within the typical values for SCLs (0.38–1.44 MPa) [74].
To gain further insight into the effects of the sterilization technique on the hydrogel
structure, the FTIR–ATR spectra of AF1, AF6, AF6ni, and AF6i dried discs before and
after SH and HPP sterilization were compared (Figure S4 in Supplementary Materials).
The spectra were normalized taking as a reference the main absorption peak of HEMA at
1704 cm−1, corresponding to the C=O band [75]. AF1, which lacks functional monomers,
showed the typical bands of pHEMA networks with strong intensities at 1483 (CH2),
1367 (CH2), 1153, and 1073 (C–O–C) cm−1. Relevantly, none band of AF1 was altered after
sterilization by either steam heat or HHP. The spectra of nonsterilized AF6, AF6ni, and AF6i
evidenced a relative increase in the bands at 1367, 1153, 1073, and 965–938 cm−1, which
can be attributed to the copolymerization with APMA. Relevantly, the sterilization did not
cause significant changes in the spectrum bands with respect to the nonsterilized discs.
Unfortunately, FTIR spectra were not useful to analyze atorvastatin–hydrogel interactions
probably because of the relatively low content in the drug.
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did not cause significant changes in the spectrum bands with respect to the nonsterilized 
discs. Unfortunately, FTIR spectra were not useful to analyze atorvastatin–hydrogel in-
teractions probably because of the relatively low content in the drug. 
Concerning the drug, as a first step, the effect of the different sterilization processes 
on the atorvastatin stability was evaluated. The UV–Vis spectra of the drug solutions 
acquired before and after steam heat (121 °C, 1 bar for 1 h) and HHP sterilization (600 
MPa, 10 min, and 70 °C) (Figure S5 in Supplementary Materials) were quite similar to 
that of nonprocessed solution. A strong decrease in the absorbance was recorded after 
gamma-radiation (25 kGy), indicating that the drug suffered degradation. Previous 
studies have shown that many drugs (e.g., moxifloxacin, ketorolac, diclofenac) degrade 
when exposed to gamma radiation in solution [43] due to the presence of free radicals 
and ions formed during the radiolysis of water [76]. Atorvastatin stability during steam 
heat and HHP was further investigated by HPLC (Figure S6 in Supplementary Materi-
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Figure 7. Elastic modulus (MPa) obtained for all hydrogels hydrated with 0.9% NaCl before and after
each sterilization method. (*) Statistically different from the nonsterilized hydrogels (Kruskal–Wallis
test and Games–Howell post hoc test, p < 0.05).
Concerning the drug, as a first step, the effect of the different sterilization processes
on the atorvastatin stability was evaluated. The UV–Vis spectra of the drug solutions
acquired before and after steam heat (121 ◦C, 1 bar for 1 h) and HHP sterilization (600 MPa,
10 min, and 70 ◦C) (Figure S5 in Supplementary Materials) were quite similar to that of
nonprocessed solution. A strong decrease in the absorbance was recorded after gamma-
radiation (25 kGy), indicating that the drug suffered degradation. Previous studies have
shown that many drugs (e.g., moxifloxacin, ketorolac, diclofenac) degrade when exposed
to gamma radiation in solution [43] due to the presence of free radicals and ions formed
during the radiolysis of water [76]. Atorvastatin stability during steam heat and HHP
was further investigated by HPLC (Figure S6 in Supplementary Materials). The drug was
found to be sensitive to 121 ◦C originating degradation products with retention times of
3.62, 5.98, and 6.85 min. Goel et al. also reported atorvastatin degradation when heating
the solution at 80 ◦C for 4 h [77]. Contrarily, HHP, which involved heating at 70 ◦C for
10 min and pressurize with 600 MPa did not trigger degradation.
Then, hydrogels sterilized applying gamma radiation, steam heat, or HHP were tested
again in terms of atorvastatin loading and release under the same conditions as for the
nonsterilized hydrogels. Steam heat and HHP sterilized hydrogels evidenced a small
decrease in the capability to load atorvastatin (Figure 8). This finding was especially
remarkable for nonimprinted and imprinted hydrogels prepared by combining the two
functional monomers EGPEM a AEMA (AF3ni and AF3i). This effect may be attributed
to the imp ct of the moist he t conditions on the amino a d hydr xyl groups that inter ct
with th drug by hydrogen bonds, although no changes were record d in the FTIR spectra
probably because of the relatively low molar content in functional monomers, compared
to pHEMA. Simil r results wer observed in previous studies using acrylic h drog ls
containing 80–90% of polymethyl methacrylate (PMMA) and 10–20% of HEMA [43,78], n
which steam heat sterilization decreased the amount of ketorolac and diclofenac loaded
after 14 days of loading. As expected, the amount of drug released by the sterilized discs
was lower, compared to nonsterilized hydrogels (Figure 9 and Figure S7 in Supplementary
Materials).
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Figure 8. Atorvastatin loaded, after 48 h soaking, by hydrogels that had not been sterilized (blue 
bars) and hydrogels sterilized by steam heat (orange bars) or high hydrostatic pressure (green bars) 
before the loading. Codes as in Table 1 (n = 4; mean values and standard deviations). 
After gamma-radiation sterilization, the amount of drug loaded by the hydrogels 
was remarkably low (below 1 mg/g of hydrogel, data not shown), and the amount of 
drug released was below the quantification limit. For this reason, and because gamma 
radiation triggered the degradation of the drug in an aqueous solution, this technique 
was discarded for further experiments. 
Figure 8. t t ti l , fter 48 h soaking, by hydrogels that had not been sterilized (blue
bars) and hydrogels sterilized by stea heat (orange bars) or high hydrostatic pressure (green bars)
before the loading. Codes as in Table 1 (n = 4; mean values and standard deviations).
fter gamma-radiation sterilization, the amount of drug loaded by the hydrogels was
rema kably low (below 1 mg/g of hydrogel, data not shown), and the amount of drug
released was below the quantification l mit. For this reason, and because gamma radiation
triggered the degradation of the drug in an aqueous solution, this technique wa discarded
for further experimen s.
The next step was to elucidate the feasibility of performing the sterilization by steam
heat or HHP while the hydrogels were already in the atorvastatin loading solution (one-pot
processing). This procedure could allow for loading and sterilization in one step, which
may be advantageous in terms of time and processing steps. Only the most promising
hydrogels in terms of atorvastatin affinity and network stability, i.e., those prepared with
APMA as a functional monomer (AF6, AF6ni, AF6i) were tested. The hydrogels were
immersed in atorvastatin solution (0.04 mg/mL ethanol:water 20:80 v/v) for 48 h under
magnetic stirring (150 rpm) at room temperature before steam heat or HHP sterilization.
The hydrogels sterilized with steam heat loaded less drug than the nonsterilized hydrogels
(Figure 10), which could be due to a combination of changes in the functional groups that
interact with atorvastatin and degradation of the drug. Differently, the hydrogels that
underwent HHP loaded similar amounts of atorvastatin as the nonsterilized ones. Namely,
HHP sterilization did not affect the loading of atorvastatin. As expected, the amount of
atorvastatin released from hydrogels sterilized with steam heat decreased, compared with
nonsterilized hydrogels, while sterilization by HHP did not modify the drug released
pattern (Figure 11). These results agreed well with those recorded for hydrogels that were
first sterilized and then loaded with atorvastatin, suggesting that degradation of both the
hydrogels and the drug under steam heat conditions may compromise the performance of
the hydrogels as drug-eluting contact lenses.
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Figure 9. Comparison of atorvastatin release profiles from hydrogels that had not been sterilized 
(WS) and hydrogels that had been sterilized by high hydrostatic pressure (HHP) before loading. 
(A) F3 series, (B) F4 series, (C) F5 series, and (D) F6 series. Codes as in Table 1 (n = 4; mean values 
and standard deviations). 
The next step was to elucidate the feasibility of performing the sterilization by steam 
heat or HHP while the hydrogels were already in the atorvastatin loading solution 
(one-pot processing). This procedure could allow for loading and sterilization in one 
step, which may be advantageous in terms of time and processing steps. Only the most 
promising hydrogels in terms of atorvastatin affinity and network stability, i.e., those 
prepared with APMA as a functional monomer (AF6, AF6ni, AF6i) were tested. The hy-
drogels were immersed in atorvastatin solution (0.04 mg/mL ethanol:water 20:80 v/v) for 
48 h under magnetic stirring (150 rpm) at room temperature before steam heat or HHP 
sterilization. The hydrogels sterilized with steam heat loaded less drug than the nonster-
ilized hydrogels (Figure 10), which could be due to a combination of changes in the 
functional groups that interact with atorvastatin and degradation of the drug. Different-
ly, the hydrogels that underwent HHP loaded similar amounts of atorvastatin as the 
nonsterilized ones. Namely, HHP sterilization did not affect the loading of atorvastatin. 
As expected, the amount of atorvastatin released from hydrogels sterilized with steam 
heat decreased, compared with nonsterilized hydrogels, while sterilization by HHP did 
Fig re 9. Comparison of atorvastatin release profiles from hydrogels that had not been sterilized
(WS) and hydrogels that had been sterilized by high hydrostatic pressure (HHP) before loading.
(A) F3 series, (B) F4 series, (C) F5 series, and (D) F6 series. Codes as in Table 1 (n = 4; mean values
and standard deviations).
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3.6. Cornea and Sclera Permeability and Accumulation 
Ex vivo permeability tests were carried out with the most promising hydrogels 
(AF6, AF6ni, and AF6i) to evaluate their capability of providing therapeutic amounts of 
atorvastatin to the eye structures. The amount of atorvastatin released from the hydro-
gels towards the donor chamber (filled with simulated lachrymal fluid) and then diffused 
toward cornea and sclera tissues, and the receptor medium was monitored by HPLC. An 
atorvastatin solution (60 µg/mL in ethanol:water 20:80 v/v, 1 mL) was also used as a con-
trol. The tests were performed using cornea and sclera tissues from porcine cattle since 
the porcine eyes are reported to present the most similar anatomical properties to the 
human eyes [79]. 
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solution by means of steam heat or high hydrostatic pressure, compared to nonsterilized hydrogels.
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Figure 11. o ariso of atorvastatin release profiles in SLF from AF6 (A), AF6ni (B), and AF6i (C) hydrogels that had not
been sterilized (WS) or that were sterilized during loading (immersed in drug solution) by means of steam heat (SH) or high
hydrostatic pressure (HHP). Codes as in Table 1 (n = 4; mean values and standard deviations).
3.6. Cornea and Sclera Permeability and Accumulation
Ex vivo permeability tests were carried out with the most promising hydrogels (AF6,
F6ni, and AF6i) to evaluate their capability of providing therapeutic amounts of atorvas-
tatin to the eye structure . The amount of atorvastatin rele ed from the hydr gels towards
the d nor chamber (filled with simu ated lachry a fluid) and then diffused toward cornea
and sclera tissues, and the rec ptor medium was onitored by HPLC. An atorvastatin
solution (60 µg/mL in ethanol:water 20:80 v/v, 1 mL) was also used as a control. The tests
were performed using cornea and sclera tissues from porcine cattle since the porcine eyes
ar reported to pres nt the most similar anatomical properties to the human eyes [79].
Regarding the concentration of atorvastatin in the donor chamber after 6 h of exper-
iment, these values were 28.43 ± 0.43 µg/mL for AF6, 19.67 ± 1.68 µg/mL for AF6ni
and 22.00 ± 0.51 µg/mL for AF6i for cornea tissue (Figure 12A). For scleral tissue, the
concentration of drug in the donor chamber was significantly lower for all hydrogels (21.32
± 3.40 µg/mL for AF6; 13.17 ± 0.63 µg/mL for AF6ni; and 15.46 ± 1.81 µg/mL for AF6i;
ANOVA, p < 0.05). In the case of the control solution, the concentration of atorvastatin
remaining in the donor chamber was still significantly high in contact with cornea and
sclera tissues (54.31 ± 2.98 and 52.11 ± 0.64 µg/mL, respectively) and, in all cases, greater
than that recorded for the hydrogels (ANOVA, p < 0.05).
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In a reported preclinical study, atorvastatin calcium formulated as eye drops (50 µM 
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Finally, since during CL wearing the hydrogels are exposed to daylight, drug sta-
bility against UV–Vis radiation may be critical for the successful development of a 
drug-eluting CL. Atorvastatin in solution was exposed to white light (fluorescent lamp) 
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Figure 12. Amounts of atorvastatin in the donor chamber (A) and accumulated in cornea and sclera
tissues (B) after 6 h of contact with drug-loaded hydrogels (AF6, AF6ni, and AF6i) and atorvastatin
solution (60 µg/mL in ethanol:water 20:80 v/v, 1 mL). Codes as in Table 1 (n = 3; mean values and
sta ar e iations).
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Amounts accumulated in cornea were 1.03± 0.04 µg/cm2 for AF6, 0.78± 0.19 µg/cm2
for AF6ni and 0.99 ± 0.04 µg/cm2 for AF6i (Figure 12B). These values were statistically
different from those obtained for the atorvastatin solution (6.47 ± 0.41 µg/cm2, ANOVA,
p < 0.05). In sclera, atorvastatin accumulation was higher and no statistical differences
were observed between the drug-loaded hydrogels and the control drug solution (ANOVA,
p = 0.78).
The amount of atorvastatin in the receptor chambers was below the quantification
limit in the time frame of the study. This means that atorvastatin mainly accumulated into
the cornea and sclera tissues but did not progress further or the diffusion was too slow to
be detected.
In a reported preclinical study, atorvastatin calcium formulated as eye drops (50 µM
drug concentration) was instilled 1 drop 8 times a day for 4 weeks in patients with ble-
pharitis and dry eye, showing tear film stabilization and anti-inflammatory effects [16].
Therefore, in each instillation, roughly 0.6 µg drug dose was applied onto the cornea, and
this amount could rapidly vanish due to lachrymal fluid turnover. The hydrogels designed
in the present work provided amounts of atorvastatin accumulated in the cornea and sclera
that may be considered therapeutically effective.
3.7. Stability of Atorvastatin Calcium Solution
Finally, since during CL wearing the hydrogels are exposed to daylight, drug stability
against UV–Vis radiation may be critical for the successful development of a drug-eluting
CL. Atorvastatin in solution was exposed to white light (fluorescent lamp) mimicking the
daylight conditions. After 8 h of exposure, UV–Vis spectrum recorded by spectrophotome-
try and HPLC runs (Figure S8 in Supplementary Materials) of atorvastatin solutions before
and after white light exposition were identical; this means that atorvastatin calcium did
not suffer any degradation. Therefore, atorvastatin loaded by the designed hydrogels is
expected to remain stable under daylight conditions, as also found in previous studies [80].
4. Conclusions
In the present work, bioinspired contact lenses were designed, for the first time, to
have an increased affinity for atorvastatin calcium by mimicking the active site of HMG–
CoA reductase. The synthesized hydrogels presented solvent uptake, light transmission,
and mechanical properties values in the common range for commercially available CLs. No
potential eye (CAM) irritation was observed neither cytotoxicity effects in Balb/3T3 cells.
The APMA hydrogels are the most promising candidates to be used as drug-eluting contact
lenses in terms of the amount of drug loaded and released. From the fabrication point
of view, loading and sterilization in the same container (one-pot processing) is a crucial
step. The loading capacity of the hydrogels and stability of atorvastatin was not affected by
HHP sterilization, which may advantageously substitute steam heat and gamma radiation
in the sterilization of atorvastatin-loaded hydrogels, maintaining atorvastatin stability
and hydrogels performance. Permeability studies through the porcine cornea and sclera
tissues revealed that the amount of atorvastatin accumulated in the cornea and sclera could
be effective to treat ocular surface diseases. The success of this first attempt to design
atorvastatin-loaded contact lenses must be contrasted with preclinical studies that confirm
their efficacy in the treatment of ocular surface diseases.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/10
.3390/pharmaceutics13050606/s1, Table S1. Fitting of Higuchi equation; Figure S1. Light transmit-
tance (%) of the hydrogels after being swollen in SLF and in drug solution; Figure S2. Atorvastatin
release profiles (%) for AF3, AF4, AF5 and AF6 hydrogels in simulated lachrymal fluid under mag-
netic stirring; Figure S3. Pictures of HET–CAM test showing the CAM after 5 min in contact with
atorvastatin-loaded discs and drug solution (0.04 mg/mL) in ethanol:water 20:80 v/v; Figure S4.
FTIR–ATR spectra obtained for nonsterilized AF6, AF6ni, and AF6i hydrogels hydrated in NaCl
0.9% and sterilized with steam heat and HHP, Figure S5. UV-Vis spectra of atorvastatin calcium
(0.04 mg/mL) solution in ethanol:water 20:80 v/v before and after steam heat, gamma-radiation and
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high hydrostatic pressure sterilization; Figure S6. HPLC chromatograms of the atorvastatin loading
solution before and after sterilization processing applying steam heat and high hydrostatic pressure;
Figure S7. Comparison of atorvastatin release profiles from hydrogels that had not been sterilized
(WS) and hydrogels that had been sterilized by steam heat (SH) before loading; Figure S8. HPLC
chromatogram of atorvastatin calcium solution (0.04 mg/mL in ethanol:water 20:80 v/v) after 8 h of
exposure to white light.
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